Up to August 9, More than 19 million people have tested positive for the novel coronavirus (SARS-CoV-2) globally, and at least 722,000 have died. In the U.S., nearly 5 million people have tested positive and more than 160,000 have died. Since the requirement for specific drugs and vaccines, as well as for effective diagnostic methods, is still urgent, Creative Diagnostics has released matched antigen pairs for serology test development, hoping to race the related research worldwide.
Now, a number of false negative results have been reported, resulting in a failure to isolate infected patients. Since titers of SARS-CoV-2 antibodies can reflect the progress of viral infection, consistent clinical manifestations suggested that antibody could act as an indicator of the stage of COVID-19 progression.
Creative Diagnostics now provides matched antigen pairs of SARS-CoV-2 Spike/RBD which are expressed in HEK293 cells, mainly covering the following products:
·Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain [His]
·Recombinant SARS-CoV-2 Spike Protein 1 [His]
·Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain [hFc]
·Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain [mFc]
These antigens are post-translationally modified (glycosylation and phosphorylation) which resemble the native viral proteins, being able to overcome specificity issues in serology assays. They can be used for research on antibodies detection to SARS-CoV-2 in double-antigen sandwich immunoassay.
“These antigen pairs have already been validated in ELISA with clinical serum samples to be of high sensitivity and specificity,” introduced by a senior scientist at Creative Diagnostics, “our products are now in stock so we’re able to deliver at short notice.”
Since the outbreak of this pandemic, Creative Diagnostics has taken actions to help fight against COVID-19 by updating various kinds of products and services. Hot products including SARS-CoV-2 antigens and antibodies, human ACE2 stable cell line – HEK293T, and recombinant SARS-CoV-2 RBD mutants are all available at Creative Diagnostics.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers for the biopharmaceutical market. It aims to provide a trusted source for all researchers’ assay development and manufacturing needs.
